Studying the mechanisms of glucose homeostasis and early diabetes, Vamsi Mootha (Massachusetts General Hospital and Broad Institute), Leif Groop (University of Malmo) and colleagues have identified a key regulator of glucose homeostasis in humans. As they report in the international open-access medical journal PLoS Medicine, TXNIP is a gene whose expression is reciprocally regulated by insulin and glucose, TXNIP levels are consistently higher than normal in patients with type 2 diabetes and prediabetes, and such elevated levels can inhibit glucose uptake in muscle and fat cells. Mootha and colleagues propose that TXNIP normally regulates and integrates glucose uptake in the periphery of the human body by acting as a glucose- and insulin-sensitive switch, and that this function becomes compromised early the development of diabetes.
Although many questions remain about the exact role of TXNIP in glucose homeostasis, the study's results help to explain many of the changes in glucose control that occur early in the development of diabetes. Furthermore, they suggest that interventions designed to modulate the activity of TXNIP might break the vicious cycle that eventually leads to type 2 diabetes.
Protein energy malnutrition is a critical, yet underestimated factor in susceptibility to infection, including the big three infectious diseases: HIV/AIDS, tuberculosis, and malaria, say researchers in a review article in PLoS Medicine.
The researchers, Ulrich Schaible (London School of Hygiene & Tropical Medicine) and Stefan Kauffman (Max Planck Institute for Infection Biology) discuss current concepts and controversies surrounding the complex influences of malnutrition on infection and immunity. They call for new strategies to overcome worldwide illness and death caused by chronic malnutrition in impoverished countries and by the newly emerging public health threat of overnutrition in industrialized societies.
plos
Robin Ali, professor of human molecular genetics at UCL says testing the technique for the first time in patients is an important and exciting step towards establishing gene therapy for the treatment of many different eye conditions.
Funding for the trial to the tune of 1 million pounds was given by the Department of Health, which says the research is pioneering and underlines Britain's leading position in gene therapy in Europe.
Using gene therapy to fix diseases caused by genetic faults is not a new idea although getting it to work in practice has proven complex.
The majority of gene therapy trials to date have been for cancer, where the process is complicated by the need to reach multiple sites in the body.
The eye is however relatively straightforward and the researchers hope that their work could lead to ways to treat more common sight problems, such as age-related macular degeneration.